Radioactive microdose reveals Drug's journey in healthy men
NCT ID NCT07578636
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 6 times
Summary
This Pfizer study in 9 healthy men uses a tiny amount of radioactive carbon to track how the experimental drug PF-07799544 is absorbed, distributed, and eliminated from the body. Participants receive the drug by mouth and by IV, and samples of blood, urine, and stool are collected. The goal is purely to understand the drug's behavior, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07799544 (with a radioactive carbon tracer)
- What this could lead to
- If successful, this study will help researchers understand how PF-07799544 is absorbed and removed from the body, which can guide future dosing and development.
- What could go wrong
- This is a very early Phase 1 study with only 9 healthy men. It is designed to gather information, not to treat any disease. The radioactive tracer is safe at these low levels, but the drug itself may have unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.